Open main menu

Psychiatrienet β

Venlafaxine-mianserine

Revision as of 19:35, 5 May 2009 by Alexandra (talk | contribs) (Created page with '{{Drugswitch | from = venlafaxine | to = mianserine | stop = * '''Day 0:''' gradually reduce dosage of duloxetine to a maximum of 75 mg/day. * '''Day 1:''' reduce a dosage o...')
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Venlafaxine
Type Antidepressant
Group SNRI
links
Medscape Venlafaxine
PubChem 5656
PubMed Venlafaxine
Kompas (Dutch) Venlafaxine
Wikipedia Venlafaxine
Mianserine
Type Antidepressant
Group other
links
PubChem 4184
PubMed Mianserine
Kompas (Dutch) Mianserine
Wikipedia Mianserine

Switch medication from venlafaxine to mianserine.[1] [2]

Nietinrijdenbord.png Stop venlafaxine
  • Day 0: gradually reduce dosage of duloxetine to a maximum of 75 mg/day.
  • Day 1: reduce a dosage of venlafaxine from 75 mg/day to 37,5 mg/day.
Eenrichtingbord.png Start mianserine
  • Day 1: simultaneously start administration of mianserine in a dosage of 30 mg/day.
  • Day 8: stop administration of venlafaxine and continue administration of mianserine only. If necessary, increase dosage of mianserine to 40-60 mg/day.
Infobord.png More information
  • Venlafaxine is a weak inhibitor of CYP2D6, which metabolizes mianserine.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.